Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Christopher J. Sweeney, Kobe Yuen et al.|Nature Medicine|2022Cited by 241
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Évanguelos Xylinas et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Ken Herrmann, Alberto Bossi et al.|European Journal of Cancer|2023Cited by 156
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinomaYing Waeckerle‐Men, Silke Gillessen, M. Fopp et al.|Cancer Immunology Immunotherapy|2006Cited by 118